2. Metabolic Enzyme/Protease Apoptosis
  3. Endogenous Metabolite Bcl-2 Family Apoptosis
  4. trans-Vaccenic acid

trans-Vaccenic acid  (Synonyms: trans-バクセン酸)

製品番号: HY-113427 純度: 98.0%
COA 取扱説明書 Technical Support

trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

trans-Vaccenic acid

trans-Vaccenic acid 構造式

CAS 番号 : 693-72-1

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 71 在庫あり
Solution
10 mM * 1 mL in DMSO USD 71 在庫あり
Solid
5 mg $65 在庫あり
10 mg $100 在庫あり
25 mg $180 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Other Forms of trans-Vaccenic acid:

trans-Vaccenic acid 関連抗体

Top Publications Citing Use of Products

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Human Endogenous Metabolite Microbial Metabolite

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity[1][2][3].

IC50 & Target

Human Endogenous Metabolite

 

体外実験

trans-Vaccenic acid is reduced in the rumen to form stearic acid or is desaturated by Δ9-desaturase in the mammary tissue to produce cis-9, trans-11 C18:2, which is an abundant conjugated Linoleic acid isomer in meat and milk[1].
trans-Vaccenic acid (0-200 μM; 24 h) inhibits NPC cell viability in a dose-dependent manner[2].
trans-Vaccenic acid (25-100 μM; 24 h) induces apoptosis in NPC cells in a dose-dependent manner. trans-Vaccenic acid significantly increases the levels of cleaved PARP and cleaved caspase-3 in a time-dependent manner[2].
trans-Vaccenic acid (25-100 μM; 24 h) induces apoptosis in NPC cells through Akt and bad inactivation[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

trans-Vaccenic acid 関連抗体

Cell Viability Assay[2]

Cell Line: The human NPC cell lines 5-8F and CNE-2
Concentration: 0 μM, 25 μM, 50 μM, 100 μM, 200 μM
Incubation Time: 24 h
Result: The growth inhibitory ratios of 5-8F cells treated with 25, 50, 100 and 200 μM were 10.8, 18.9, 49.3 and 80.2%, respectively, and those of CNE-2 cells were 7.9, 15.2, 45.3 and 70.5%, respectively.

Apoptosis Analysis[2]

Cell Line: The human NPC cell lines 5-8F and CNE-2
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Incubation of 5-8F cells with 25, 50 or 100 μM for 24 h caused 7.67, 12.9% or 35% increases in total apoptosis, respectively.
Similarly, after incubation with 25 50 or 100 μM CNE-2, the percentage of apoptotic cells was increased by 12.9, 15.1% or 22.3%, respectively. Significantly increased the levels of cleaved PARP and cleaved caspase-3 in a time-dependent manner.

Western Blot Analysis[2]

Cell Line: The human NPC cell lines 5-8F and CNE-2
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Induced a decrease in Bad phosphorylation on Ser-136 and Ser-112 in a concentration-dependent manner.
Protein kinases such as Akt phosphorylate Bad at Ser136, thereby blocking Bad-induced apoptosis.
The expression levels of p-Akt were significantly reduced in a dose-dependent manner.
体内実験

trans-Vaccenic acid (1% w/w; diet; for 8 weeks) alleviates features of metabolic syndrome (MetS) potentially by remodeling adipose tissue and attenuating ectopic lipid accumulation in a rat model of obesity and MetS[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Obese JCR:LA-cp rats[3].
Dosage: 1% w/w
Administration: Diet; for 8 weeks
Result: Reduced total body fat and decreased adipocyte size.
Increased metabolic rate concomitantly with an increased preference for whole-body glucose utilization for oxidation and increased insulin sensitivity.
Decreased nonalcoholic fatty liver disease activity scores and reduced hepatic and intestinal triglyceride secretion, while exerting differential transcriptional regulation of SREBP1 and FAS amongst other key genes in the liver and the intestine.
分子量

282.46

分子式

C18H34O2
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

CCCCCC/C=C/CCCCCCCCCC(O)=O
Structure Classification
Initial Source

the fat of ruminants and in human dairy products
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (354.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.5403 mL 17.7016 mL 35.4032 mL
5 mM 0.7081 mL 3.5403 mL 7.0806 mL
10 mM 0.3540 mL 1.7702 mL 3.5403 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.85 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (8.85 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  Corn Oil

    Solubility: 50 mg/mL (177.02 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 98.0%

COA (238 KB) HNMR (244 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.5403 mL 17.7016 mL 35.4032 mL 88.5081 mL
5 mM 0.7081 mL 3.5403 mL 7.0806 mL 17.7016 mL
10 mM 0.3540 mL 1.7702 mL 3.5403 mL 8.8508 mL
15 mM 0.2360 mL 1.1801 mL 2.3602 mL 5.9005 mL
20 mM 0.1770 mL 0.8851 mL 1.7702 mL 4.4254 mL
25 mM 0.1416 mL 0.7081 mL 1.4161 mL 3.5403 mL
30 mM 0.1180 mL 0.5901 mL 1.1801 mL 2.9503 mL
40 mM 0.0885 mL 0.4425 mL 0.8851 mL 2.2127 mL
50 mM 0.0708 mL 0.3540 mL 0.7081 mL 1.7702 mL
60 mM 0.0590 mL 0.2950 mL 0.5901 mL 1.4751 mL
80 mM 0.0443 mL 0.2213 mL 0.4425 mL 1.1064 mL
100 mM 0.0354 mL 0.1770 mL 0.3540 mL 0.8851 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

trans-Vaccenic acid Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

trans-Vaccenic acid693-72-1Endogenous MetaboliteBcl-2 FamilyApoptosisInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
trans-Vaccenic acid
製品番号:
HY-113427
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.